| Literature DB >> 35268511 |
Franz Haertel1,2, Diana Reisberg2,3, Martin Peters2,4, Sebastian Nuding2,5, P Christian Schulze1, Karl Werdan2, Henning Ebelt2,6.
Abstract
BACKGROUND: Acute kidney injury (AKI) is associated with an increased mortality in critically ill patients, especially in patients with multiorgan dysfunction syndrome (MODS). In daily clinical practice, the grading of AKI follows the Kidney Disease: Improving Global Outcomes (KDIGO) criteria. In most cases, a relevant delay occurs frequently between the onset of AKI and detectable changes in creatinine levels as well as clinical symptoms. The aim of the present study was to examine whether a near infrared spectroscopy (NIRS)-based, non-invasive ischemia-reperfusion test (vascular occlusion test (VOT)) together with unprovoked (under resting conditions) tissue oxygen saturation (StO2) measurements, contain prognostic information in the early stage of MODS regarding the developing need for renal replacement therapy (RRT).Entities:
Keywords: MODS; acute kidney injury; intensive care; tissue oxygen saturation
Year: 2022 PMID: 35268511 PMCID: PMC8911273 DOI: 10.3390/jcm11051420
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Baseline data of the total study population regarding RRT status.
| Study Population | |||
|---|---|---|---|
| No RRT | RRT | ||
| ( | ( | ||
|
| |||
| Age (years, mean ± SD) | 64.5 ± 15.0 | 59.4 ± 13.2 | n.s. |
| Male ( | 25 (73.5) | 15 (68.2) | n.s. |
| Female ( | 9 (26.5) | 7 (31.8) | n.s. |
| BMI (kg/m2, mean ± SD) | 27.6 ± 8.9 | 24.9 ± 4.6 | n.s. |
| BSA (m2, mean ± SD) | 1.96 ± 0.29 | 1.91 ± 0.21 | n.s. |
| <70 years ( | 18 (52.9) | 16 (47.1) | n.s. |
| ≥70 years ( | 16 (47.1) | 6 (27.3) | n.s. |
|
| |||
| StO2 unprovoked (%, mean ± SD) | 82 ± 10.8 | 82.1 ± 10.9 | n.s. |
| Occlusion slope (%/min, mean ± SD) | −11.7 ± 4.1 | −9.1 ± 3.7 | 0.02 |
| Recovery slope (%/s, mean ± SD) | 2.3 ± 1.6 | 1.7 ± 0.9 | 0.01 |
|
| |||
| APACHE II score (mean ± SD) | 33.4 ± 6.2 | 36.3 ± 6.4 | n.s. |
| Creatinine level (µmol/L) | 157.9 ± 77.0 | 209. 9 ± 121.3 | n.s. |
| BUN (mmol/L, mean ± SD) | 13.8 ± 10.2 | 16.4 ± 8.6 | n.s. |
| Urinary output (mL/h/m2 BSA, mean ± SD) | 53.4 ± 14.9 | 21.6 ± 47.1 | 0.001 |
| Urinary output (ml/h/kg, mean ± SD) | 1.3 ± 0.2 | 0.5 ± 1.0 | <0.001 |
| Body temperature (°C, mean ± SD) | 37.0 ± 1.4 | 36.9 ± 1.3 | n.s. |
| CRP (mg/L, mean ± SD) | 186.0 ± 144.1 | 258.2 ± 173.4 | n.s. |
| Invasive mechanical ventilation ( | 32 (94.1) | 20 (90.1) | n.s. |
| SpO2 (%, mean ± SD) | 96.2 ± 5.8 | 95.1 ± 6.5 | n.s. |
| FiO2 (%, mean ± SD) | 73.2 ± 21.2 | 67.9 ± 19.3 | n.s. |
| pO2 (kPa, mean ± SD) | 15.7 ± 7.4 | 14.6 ± 4.9 | n.s. |
| Time of MODS diagnosis relative to ICU admission (h, mean ± SD) | 35.4 ± 31.6 | 18.2 ± 13.1 | 0.03 |
| Haemoglobin (mmol/L, mean ± SD) | 6.9 ± 1.2 | 6.4 ± 1.3 | n.s. |
| Relative norepinephrine dose (μg/kg/min, mean ± SD) | 0.46 ± 0.06 | 0.59 ± 0.12 | n.s. |
| Relative doputamine dose (μg/kg/min, mean ± SD) | 3.1 ± 0.5 | 4.3 ± 0.9 | n.s. |
|
| |||
| No AKI ( | 9 (26.5) | 0 (0) | <0.001 |
| Stage I ( | 11 (32.4) | 0 (0) | <0.001 |
| Stage II ( | 14 (41.1) | 0 (0) | <0.001 |
| Stage III ( | 0 (0) | 22 (100) | <0.001 |
|
| |||
| Cardiogenic MODS ( | 9 (26.5) | 6 (27.3) | n.s. |
| Septic MODS ( | 25 (73.5) | 16 (72.7) | n.s. |
|
| |||
| Hypertension ( | 17 (50) | 7 (31.8) | n.s. |
| Diabetes ( | 12 (35.3) | 5 (22.7) | n.s. |
| CKD ( | 3 (8.8) | 3 (13.6) | n.s. |
| Past myocardial infarction ( | 7 (20.6) | 5 (22.7) | n.s. |
| Past stroke ( | 1 (2.9) | 1 (4.5) | n.s. |
| Active malignancy ( | 7 (20.6) | 4 (18.2) | n.s. |
AKI, acute kidney injury; KDIGO, Kidney Disease: Improving Global Outcomes; APACHE II score, acute physiology and chronic health evaluation II score; BMI, body mass index; CRP, C-reactive protein; MODS, multiorgan dysfunction syndrome; CKD, chronic kidney disease; ICU, intensive care unit; RRT, renal replacement therapy; SpO2, peripheral oxygen saturation (measured by pulse oximetry); N, number of patients; n.s., not significant; BSA, body surface area; h, hour; BUN, blood urea nitrogen; p < 0.05, statistically significant.
Figure 1Unprovoked StO2 and the VOT occlusion and recovery slopes at baseline and after 96 h, in the context of renal replacement therapy (RRT) status until day 28.
Figure 2Mean ± standard deviation for unprovoked StO2 and the VOT parameters OS and RS at baseline, regarding the stages of acute kidney injury (AKI) according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Bonferroni correction for OS: no AKI vs. AKI stage III, p = 0.036; no AKI vs. AKI stage I/AKI stage II, p > 0.05; AKI stage I vs. AKI stage II/AKI stage III, p > 0.05. Bonferroni correction for RS: no AKI vs. AKI stage III, p = 0.007; no AKI vs. AKI stage I/AKI stage II, p > 0.05; AKI stage I vs. AKI stage II/AKI stage III, p > 0.05. Bonferroni correction for unprovoked StO2: no AKI vs. AKI stage III, p > 0.05; no AKI vs. AKI stage I/AKI stage II, p > 0.05; AKI stage I vs. AKI stage II/AKI stage III, p > 0.05.
Figure 3Percentage of patients developing the need for renal replacement therapy in relation to their VOT occlusion slope at baseline; p = 0.045.
Figure 4Forrest plot showing the unadjusted and adjusted odds ratios regarding the prediction of renal replacement therapy. APACHE II, acute physiology and chronic health evaluation.
Unprovoked StO2, VOT parameters, APACHE II score, and creatinine level at baseline and their respective AUC values, regarding the prediction of renal replacement therapy.
| AUC | CI (95%) | ||
|---|---|---|---|
|
| |||
| StO2, unprovoked | 0.52 | 0.36–0.67 | n.s. |
| Occlusion slope | 0.70 | 0.54–0.84 | 0.04 |
| Recovery slope | 0.59 | 0.44–0.74 | n.s. |
|
| |||
| Creatinine level | 0.64 | 0.47–0.83 | n.s. |
| Blood urea nitrogen | 0.61 | 0.48–0.74 | n.s. |
| Urinary output | 0.94 | 0.85–1.0 | <0.001 |
| APACHE II score | 0.63 | 0.47–0.78 | n.s. |
APACHE II score, acute physiology and chronic health evaluation II score; AUC, area under the curve; CI, confidence interval; VOT, vascular occlusion test; n.s., not significant; p < 0.05, statistically significant.
Figure 5The VOT occlusion slopes at baseline regarding 28-day mortality for patients receiving RRT (A) and patients not needing RRT (B), as well as the VOT recovery slopes at baseline regarding 28-day mortality for patients receiving RRT (C) and patients not needing RRT (D), using Kaplan–Meier survival curves; level of significance measured by p.